We are seeking a scientist to join our dynamic, multi-disciplinary team, focused on designing, making and expanding the synthetic repertoire of our encoded synthetic chemistry libraries for application in our totally integrated drug discovery platform.
Repare was founded by leading experts at the forefront of DNA damage and repair cancer biology and genome-scale synthetic lethal screening technologies. The company has assembled a seasoned team of industry veterans and a world-class Advisory Board to support the development of next generation precision oncology, small-molecule therapeutics.
Repare is backed by tier-one strategic and institutional biotechnology investors with track records for high-impact drug development, including Versant Ventures and MPM Capital.
Expertise in cell culture is an asset. Candidates must have the ability to communicate clearly, collaborate and enjoy a fast-paced and hands-on research environment.
Design and develop medium-to-high throughput biochemical ie. Work closely with project teams and external CROs to deploy biochemical assays for high-throughput screening and to drive SAR development. Biopharmaceutical industry experience is highly preferred Advanced knowledge and demonstrable track record in enzymology and enzyme inhibitor mechanism-of-action studies Significant experience in developing robust enzyme-based assays to support high-throughput screening or medicinal chemistry efforts with a successful record of compound progression Skilled in data analysis and reporting IC50, EC50, assay variability assessment etc.This course is designed to provide an overview on epidemiology and the Internet for medical and health related students around the world based on the concept of Global Health Network University and Hypertext Comic Books.
We are advancing a pipeline of novel mRNA vaccines and therapies for multiple diseases. CV Therapeutics's detailed financings; Comprehensive pipeline breakdown, including molecular targets & partnerships. In-depth BioPharma industry analysis. In a new research consortium, scientists from the "Hopp Children's Cancer Center Heidelberg" (KiTZ), together with working groups from Ludwig Maximilian University of Munich (LMU) and the West German Cancer Centre (WTZ) of Essen University, have teamed up to advance research on Ewing sarcoma and derive approaches for novel diagnosis and therapy methods on this basis.
ETFs with exposure to Voyager Therapeutics, Inc. Here are 5 ETFs with the largest exposure to attheheels.coming the performance and risk of Voyager Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility.
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.